Seamless phase 2/3 oncology trial design with flexible sample size determination

Related Experiment Video

Updated: Dec 23, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.1K

Zhaoyang Teng1, Yuan Tian2, Yi Liu3

  • 1Servier Pharmaceuticals, Boston, Massachusetts, USA.

Statistics in Medicine
|April 28, 2020
PubMed

Insights

This study introduces a flexible sample size determination (SSD) for seamless phase 2/3 oncology trials. This innovative design improves upon fixed SSD by dynamically adjusting sample size, potentially reducing patient numbers and enhancing statistical power for faster drug development.

Area of Science:

  • Clinical Trial Design
  • Oncology Drug Development
  • Biostatistics

Background:

  • Seamless phase 2/3 designs with fixed sample size determination (SSD) are popular in oncology for efficiency.
  • However, fixed SSD can be problematic due to inaccurate treatment effect assumptions early in development.
  • Limited efficacy data at the design stage poses a challenge for conventional fixed SSD.

Purpose of the Study:

  • To propose an innovative seamless phase 2/3 study design with flexible SSD for oncology trials.
  • To address the uncertainty in treatment effect estimations during the early stages of drug development.
  • To offer an alternative to conventional fixed SSD designs by incorporating dynamic sample size adjustments.

Main Methods:

  • The proposed design utilizes a distribution of treatment effects rather than a single assumption.
  • Sample size for the phase 3 portion is determined dynamically based on observed phase 2 data.
  • Practical sample size determination rules for the final analysis are discussed.

Main Results:

  • The flexible SSD design can lead to a reduced sample size compared to conventional fixed SSD.
  • The proposed design may offer improved statistical power.
  • This approach enhances the efficiency of oncology drug development.

Conclusions:

  • The innovative seamless phase 2/3 design with flexible SSD offers advantages over traditional fixed SSD methods.
  • This design is particularly beneficial for aggressive development strategies aiming to expedite patient access to treatments.
  • Dynamic sample size determination improves trial efficiency and reliability in oncology drug development.
Keywords:
flexible designgo/no-go criteriaseamless phase 2/3 designsymmetric sample size determination rule

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.5K
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

259

Related Concept Videos

Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
90
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
Study Design in Statistics01:15

Study Design in Statistics

A study design is a set of techniques that allow a researcher to collect and analyze data from different variables defined for a specific research problem. Statistics is commonly for effective study design and more robust experiments,
Does aspirin reduce the risk of heart attacks? Is one brand of fertilizer more effective at growing roses than another? Is fatigue as dangerous to a driver as the influence of alcohol? Questions like these are answered using randomized experiments with proper...
9.9K
Sample Size Calculation01:19

Sample Size Calculation

Knowledge of the sample size is the first requirement to conduct random sampling or an experiment. The sample size is the total number of units, observations, or groups (in some cases) used to get the data to estimate a population parameter. As the name suggests, the sample size is that of the sample drawn from the population and differs from the population size.
The sample size for the given experiment or sampling effort is fundamental to any study design. Sample size decides the number of...
6.0K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
334
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
136